Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Parra

Showing results (1-10 of 98) with videos related to

Pageof 10
Sort By:
The New England Journal of Medicine|December 16, 2011
Rivaroxaban versus warfarin in nonvalvular atrial fibrillationRobert Rosenstein, David Parra
Lancet (London, England)|July 7, 2009
Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trialRobert Rosenstein, David Parra
The New England Journal of Medicine|March 13, 2009
Benazepril plus amlodipine or hydrochlorothiazide for hypertensionDavid Parra, Robert Rosenstein
Current Hypertension Reports|June 28, 2014
Current therapeutic approaches to cardio-protection in hypertensionDavid Parra, Augustus Hough
Circulation|July 1, 2009
Letter by Rosenstein and Parra regarding article, "Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel: Thrombolysis in Myocardial Infarction 38"Robert S Rosenstein, David Parra
The New England Journal of Medicine|January 6, 2010
Ticagrelor versus clopidogrel in acute coronary syndromesRobert S Rosenstein, David Parra
Revista Espanola De Enfermedades Digestivas|May 20, 2024
Different trends in stomach and pancreatic cancer mortality ratesNuria Aragonés, David Parra-Blázquez
JAMA|November 19, 2009
Biomarkers for prediction of cardiovascular eventsRobert S Rosenstein, David Parra
The New England Journal of Medicine|April 1, 2011
Cardiac-resynchronization therapyRobert S Rosenstein, David Parra
The New England Journal of Medicine|May 10, 2023
Baxdrostat for Treatment-Resistant HypertensionNicasia D'Allesandro, Augustus Hough, David Parra
Pageof 10

Showing results (1-10 of 98) with videos related to

Sort By:
Pageof 10
The New England Journal of Medicine|December 16, 2011
Rivaroxaban versus warfarin in nonvalvular atrial fibrillationRobert Rosenstein, David Parra
Lancet (London, England)|July 7, 2009
Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trialRobert Rosenstein, David Parra
The New England Journal of Medicine|March 13, 2009
Benazepril plus amlodipine or hydrochlorothiazide for hypertensionDavid Parra, Robert Rosenstein
Current Hypertension Reports|June 28, 2014
Current therapeutic approaches to cardio-protection in hypertensionDavid Parra, Augustus Hough
Circulation|July 1, 2009
Letter by Rosenstein and Parra regarding article, "Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel: Thrombolysis in Myocardial Infarction 38"Robert S Rosenstein, David Parra
The New England Journal of Medicine|January 6, 2010
Ticagrelor versus clopidogrel in acute coronary syndromesRobert S Rosenstein, David Parra
Revista Espanola De Enfermedades Digestivas|May 20, 2024
Different trends in stomach and pancreatic cancer mortality ratesNuria Aragonés, David Parra-Blázquez
JAMA|November 19, 2009
Biomarkers for prediction of cardiovascular eventsRobert S Rosenstein, David Parra
The New England Journal of Medicine|April 1, 2011
Cardiac-resynchronization therapyRobert S Rosenstein, David Parra
The New England Journal of Medicine|May 10, 2023
Baxdrostat for Treatment-Resistant HypertensionNicasia D'Allesandro, Augustus Hough, David Parra
Pageof 10